Skip to main content

Warning notification:Warning

Unfortunately, you are using an outdated browser. Please, upgrade your browser to improve your experience with HSE. The list of supported browsers:

  1. Chrome
  2. Edge
  3. FireFox
  4. Opera
  5. Safari

High Grade NH Lymphoma SACT Regimens

General NHL, sALCL, DLBCL, MCL, mobilisation of peripheral blood stem cells

cycloPHOSphamide, DOXOrubicin, vinCRIStine and prednisoLONE (CHOP) Therapy– 21 days

Regimen

00841a

Treatment of Non-Hodgkin lymphoma (NHL)

Intrathecal Cytarabine 50mg

Regimen

00870c

Prophylaxis and treatment of CNS disease in Non-Hodgkin Lymphomas

Intrathecal Cytarabine 70mg

Regimen

00871c

Prophylaxis and treatment of CNS disease in Non-Hodgkin Lymphomas

Epcoritamab Monotherapy

Regimen

00896a

As monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy

Glofitamab Monotherapy

Regimen

00935a

As monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B‑cell lymphoma (DLBCL), after two or more lines of systemic therapy

Hyper CVAD (ALL) Therapy - Part A

Regimen

Indication

00824b

Treatment of adult patients ≥ 25 years with Ph negative acute lymphoblastic lymphoma

riTUXimab Hyper CVAD (ALL) Therapy - Part A

Regimen

Indication

00825b

Treatment of adult patients ≥ 25 years with CD20 positive, Ph negative acute lymphoblastic lymphoma

Hyper CVAD (ALL) Therapy - Part B (Patients ≤ 60 years)

Regimen

Indication

00826b

Treatment of adult patients 25-60 years with Ph negative acute lymphoblastic lymphoma

Hyper CVAD (ALL) Therapy - Part B (Patients > 60 years)

Regimen

Indication

00932b

Treatment of adult patients > 60 years with Ph negative acute lymphoblastic lymphoma

riTUXimab Hyper CVAD (ALL) Therapy - Part B (Patients ≤ 60 years)

Regimen

Indication

00827b

Treatment of adult patients 25-60 years with CD20 positive, Ph negative acute lymphoblastic lymphoma

riTUXimab Hyper CVAD (ALL) Therapy - Part B (Patients > 60 years)

Regimen

Indication

00933b

Treatment of adult patients > 60 years with CD20 positive, Ph negative acute lymphoblastic lymphoma

Hyper CVAD (ALL) Maintenance Therapy (POMP)

Regimen

Indication

00912b

Maintenance therapy for adult patients ≥ 25 years with Ph negative acute lymphoblastic lymphoma

riTUXimab and Bendamustine Therapy

Regimen

00345a

Treatment of patients with previously untreated indolent CD20-positive, stage III-IV Non-Hodgkin lymphoma (NHL).

R-CEOP Therapy

Regimen

00510a

Treatment of Non-Hodgkin CD20 positive Lymphoma for patients not suitable for anthracycline therapy

(*riTUXimab) cycloPHOSphamide, DOXOrubicin, vinCRIStine and prednisoLONE (*R)-CHOP Therapy– 14 days

Regimen

00409a

Treatment of Non-Hodgkin Lymphoma (NHL)*

*riTUXimab to be included in CD20 positive patients

(*riTUXimab) cycloPHOSphamide, DOXOrubicin, VinCRIStine and prednisoLONE (*R)-CHOP) Therapy– 21 days

Regimen

00307a

Treatment of Non-Hodgkin Lymphoma (NHL).*

*riTUXimab to be included in CD20 positive patients.

riTUXimab S/C, cycloPHOSphamide, DOXOrubicin, vinCRIStine and prednisoLONE (R-CHOP) Therapy – 21 Days

Regimen

00667a

Treatment of Non-Hodgkin Lymphoma (NHL)

(R**)- miniCHOP Therapy – 21 days

Regimen

00436a

Treatment of Non-Hodgkin Lymphoma in patients aged greater than 80 or with significant co-morbidities.

* riTUXimab to be included in all CD20 positive patients.

(R*)-ICE ((riTUXimab*), Ifosfamide, CARBOplatin and Etoposide) Therapy - Outpatient

Regimen

00751a

Treatment of relapsed/refractory Non-Hodgkin Lymphoma (NHL)*

(R**)-DHAP Therapy

Regimen

00395a

Treatment of relapsed Non-Hodgkin Lymphoma**

**riTUXimab to be included in CD20 positive patients

riTUXimab, dexAMETHasone, Cytarabine and Oxaliplatin ((*R)-DHAOx) Therapy

Regimen

00834a

Treatment of relapsed Non Hodgkin’s Lymphoma*

*riTUXimab to be included in CD20 postitive patients

00834c

First line treatment of mantle cell lymphoma

(R*)-ESHAP Therapy

Regimen

00394a

Treatment of relapsed Non-Hodgkin Lymphoma

riTUXimab** Gemcitabine and CISplatin ((R**)-GDP) Therapy

Regimen

00441a

Treatment of relapsed Non-Hodgkin Lymphoma

(R**)-ICE ((riTUXimab), Ifosfamide, CARBOplatin and Etoposide) Therapy

Regimen

00397a

Treatment of relapsed/refractory Non-Hodgkin Lymphoma**

**riTUXimab to be included in CD20 positive patients.

ICE (Ifosfamide, CARBOplatin and Etoposide) Therapy

Regimen

00842a

Treatment of relapsed/refractory Non-Hodgkin Lymphoma

(*riTUXimab)-Gemcitabine, cycloPHOSphamide, vinCRIStine and prednisoLONE (*R)-GCVP) Therapy–21 days

Regimen

00737a

Treatment of high-grade Non-Hodgkin Lymphoma in patients who are unsuitable for R-CHOP due to impaired cardiac function or other co-morbidities*

* riTUXimab to be included in CD20 positive patients

ESHAP Therapy

Regimen

00838a

Treatment of relapsed Non-Hodgkin Lymphoma

Intrathecal Methotrexate for haematological malignancies

Regimen

00869c

Prophylaxis and treatment of CNS disease in Non-Hodgkin Lymphomas

Pixantrone Therapy

Regimen

00255a

Monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive Non-Hodgkin B-cell Lymphomas (NHL).

The benefit of pixantrone treatment has not been established in patients when used as fifth line or greater chemotherapy in patients who are refractory to last therapy.

High dose Methotrexate, high dose Cytarabine, riTUXimab and Thiotepa (MATRix)Therapy

Regimen

00508b

Treatment of CNS relapse of a high grade systemic lymphoma

Brentuximab vedotin and cycloPHOSphamide DOXOrubicin and prednisoLONE (CHP) Therapy

Regimen

00801a

Brentuximab vedotin in combination with cycloPHOSphamide, DOXOrubicin and prednisoLONE (CHP) for use in adult patients with previously untreated systemic anaplastic large cell lymphoma (sALCL)

Polatuzumab Vedotin, Bendamustine and riTUXimab Therapy

Regimen

00685a

Polatuzumab Vedotin in combination with bendamustine and riTUXimab for the treatment of adult patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) who are not candidates for haematopoietic stem cell transplant

Dose Adjusted riTUXimab, Etoposide, prednisoLONE, DOXOrubicin, cycloPHOSphamide and vinCRIStine (DA-R EPOCH)

Regimen

00355a

Treatment of patients with CD20 positive diffuse large B-cell Non-Hodgkin lymphoma (NHL).

Dose Adjusted riTUXimab S/C, Etoposide, prednisoLONE, DOXOrubicin, cycloPHOSphamide and vinCRIStine (DA-R(S/C) EPOCH) Therapy

Regimen

00672a

Treatment of patients with CD20 positive diffuse large B-cell Non-Hodgkin lymphoma (NHL)

R-Gemcitabine (1000mg/m2) Oxaliplatin Therapy - 14 day

Regimen

00506a

Relapsed or refractory CD20 positive diffuse large B cell lymphoma in patients ineligible for stem cell transplant.

Polatuzumab Vedotin, riTUXimab, cycloPHOSphamide, DOXOrubicin and prednisoLONE Therapy

Regimen

00833a

Polatuzumab Vedotin in combination with riTUXimab, cycloPHOSphamide, DOXOrubicin and prednisoLONE for the treatment of adult patients with previously untreated diffuse large B-cell lymphoma (DLBCL)

Nordic Therapy Protocol

Regimen

00393a

Mantle Cell Lymphoma

riTUXimab and Bendamustine Therapy

Regimen

00345b

Treatment of patients with previously untreated CD20-positive, stage III-IV mantle cell lymphoma (MCL), ineligible for autologous stem cell transplant.

riTUXimab-Hyper CVAD Therapy (MCL)-Part A

Regimen

00466a

Treatment of adult patients with mantle cell lymphoma

riTUXimab-Methotrexate and Cytarabine Therapy (MCL)-Hyper CVAD Part B

Regimen

00467a

Treatment of adult patients with mantle cell lymphoma

Ibrutinib Therapy - Mantle Cell Lymphoma

Regimen

00297a

As a single agent for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL)

cycloPHOSphamide 2000mg/m2 For Stem Cell Mobilisation

Regimen

00438a

Mobilisation of peripheral blood stem cells for future stem cell rescue following high dose chemotherapy

Plerixafor and G-CSF Therapy

Regimen

00536a

Is indicated in combination with granulocyte-colony stimulating factor (G-CSF) to enhance mobilisation of haematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in adult patients with lymphoma and multiple myeloma whose cells mobilise poorly

Tafasitamab and Lenalidomide Therapy

Regimen

00774a

Tafasitamab in combination with lenalidomide followed by tafasitamab monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant (ASCT).

cycloPHOSphamide 1500mg/m2 For Stem Cell Mobilisation

Regimen

00795a

Mobilisation of peripheral blood stem cells for future stem cell rescue following high dose chemotherapy

High Dose Methotrexate (3000mg/m2) Therapy – 24 hour infusion (CNS prophylaxis)

Regimen

00665a

High grade lymphoma with high risk of CNS involvement.

High Dose Methotrexate (3000mg/m2) Therapy 3 hour infusion (CNS prophylaxis)

Regimen

00439a

High grade lymphoma with high risk of CNS involvement.

Brentuximab vedotin Monotherapy

Regimen

00234c

Treatment of adult patients with relapsed or refractory systemic anaplastic large cell lymphoma (sALCL)

Zanubrutinib Therapy

Regimen

Indication

00708d

As monotherapy for the treatment of adult patients with relapsed/refractory marginal zone lymphoma, who have received at least one prior anti-CD20-based therapy

Back to National Cancer Control Programme